E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer

Cancer Gene Therapy

Volumn 16, Issue 2, 2009, Pages 126-136

  Fukuda, K ^a   Abei, M ^a   Ugai, H ^b,d   Kawashima, R ^a,b   Seo, E ^a   Wakayama, M ^a   Murata, T ^b   Endo, S ^a   Hamada, H ^c   Hyodo, I ^a   Yokoyama, K K ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Carcinoembryonic antigen; Gallbladder cancer; Suicide gene

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GANCICLOVIR; HERPESVIRUS VECTOR; ONCOLYTIC ADENOVIRUS; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; FEMALE; GALLBLADDER CANCER; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANIMALS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; FEMALE; GALLBLADDER NEOPLASMS; GENE THERAPY; HELA CELLS; HUMANS; MICE; MICE, SCID; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; MUS; SIMPLEXVIRUS;

EID: 58349108062     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.67     Document Type: Article

References (50)

1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-176.
2. Donohue JH, Stewart AK, Menck HR. The national cancer data base report on carcinoma of the gallbladder, 1989-1995. Cancer 1998; 83: 2618-2628.
3. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54: 5258-5261.
4. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 1996; 56: 1341-1345.
5. Tanaka T, Kanai F, Lan K-H, Ohashi M, Shiratori Y, Yoshida Y et al. Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. Biochem Biophys Res Commun 1997; 231: 775-779.
6. Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther 1998; 5: 1363-1371.
7. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55: 5283-5287.
8. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81.
9. Kijima T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H et al. Application of the Cre recombinase/lox P system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res 1999; 59: 4906-4911.
10. Nyati MK, Sreekumar A, Li S, Zhang M, Rynkiewicz SD, Chinnaiyan AM et al. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res 2002; 62: 2337-2342.
11. Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmented transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene-regulatory system. Mol Ther 2001; 3: 278-283.
12. Chiocca EA. Oncolytic viruses. Nat Rev 2002; 2: 938-950.
13. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005; 12: 141-161.
14. Ries S, Korn WM. ONYX-015: mechanism of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002; 86: 5-11.
15. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
16. Heise C, Hermiston T, Johnson L, Brooks G, Jhoannes AS, Williams A et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
17. Doronin S, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WSM. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000; 74: 6147-6155.
18. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470-9478.
19. Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999; 73: 5333-5344.
20. Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, Zwiebel J et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003; 9: 693-702.
21. Wadler S, Yu B, Tan J-Y, Kaleya R, Rozenblit A, Makower D et al. Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gallbladder carcinoma implants. Clin Cancer Res 2003; 9: 33-43.
22. Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T et al. E1A, E1B double-restricted oncolytic adenovirusfor gene therapy of gallbladder cancer. Cancer Res 2003; 63: 4434-4440.
23. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H et al. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 2004; 23: 1821-1828.
24. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312.
25. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double-suicide gene, and radiotherapy. Human Gene Ther 1998; 9: 1323-1333.
26. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Human Gene Ther 2000; 11: 67-76.
27. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410-413.
28. Wildner O, Morris JC, Vahanian NN, Ford Jr H, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6: 57-62.
29. Nanda D, Vogels R, Havenga H, Azezaat CJ, Bout A, Smit PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001; 61: 8743-8750.
30. Morris JC, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56-62.
31. Wildner O, Morris JC. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 2000; 60: 4167-4174.
32. Lambright ES, Amin K, Wiewrodt R, Force SD, Lanuti M, Propert KJ, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther 2001; 8: 946-953.
33. Seo E, Abei M, Wakayama M, Fukuda K, Ugai H, Murata T et al. Effective gene therapy for biliary tract cancer by a conditionally replicative adenovirus carrying uracil phosphoribosyltransferase (UPRT) gene: Significance of timing of 5-fluorouracil administration. Cancer Res 2005; 65: 546-552.
34. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gallbladder. J Pathol 1993; 170: 67-72.
35. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996; 77: 452-458.
36. Caca K, Feisthammel J, Klee K, Tannapeel A, Witzigmann H, Wittekind C et al. Inactivation of the INK4A/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer 2002; 97: 481-488.
37. Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 gene in biliary tract cancers. Cancer Res 1995; 55: 2756-2760.
38. Shi YZ, Hui AM, Li X, Takayama T, Makuuchi M. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. Clin Cancer Res 2000; 6: 4096-4100.
39. Maxwell P, Davis RI, Sloan J. Carcinoembryonic antigen (CEA) in benign and malignant epithelium of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. J Pathol 1993; 170: 73-76.
40. Shinoura N, Yoshida Y, Tsunoda R, Ohashi M, Zhang W, Asai A et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res 1999; 59: 3411-3416.
41. bml class I MHC gene. EMBO J 1990; 9: 127-135.
42. Alemany R, Lai S, Lou Y-C, Jan H-Y, Fang X, Zhang W-W. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther 1999; 6: 21-25.
43. Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W et al. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther 2000; 11: 223-235.
44. Nagayama Y, Nakao K, Hayakawa T, Niwa M. Enhanced antitumor effect of combined replicative adenovirus and non-replicative adenovirus expressing interleukin-12 in an immunocompetent mouse model. Gene Ther 2003; 10: 1400-1403.
45. Lee C-T, Park K-H, Yanagisawa K, Adachi Y, Ohm JF, Nadaf S et al. Combination therapy with conditionally replicative adenovirus and replication defective adenovirus. Cancer Res 2004; 64: 6660-6665.
46. Liu F, Green MR. Promoter targeting by adenovirus E1A through interaction with different cellular DNA-binding domains. Nature 1994; 368: 520-525.
47. Flint J, Shenk T. Viral transactivating proteins. Annu Rev Genet 1997; 31: 177-212.
48. Hauck W, Stanners CP. Transcriptional regulation of the carcinoembryonic antigen gene. J Biol Chem 1995; 8: 3602-3610.
49. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276.
50. Sherr CJ, McCormick F. The Rb and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.